What AI Replaces In Phase 2/3 Data Management, And The Edit Check Question Your Team Hasn't Asked Yet

The conversation surrounding AI in clinical trials often oscillates between hyperbolic promises and skeptical dismissals. Moving beyond the "proof-of-concept" stage requires a grounded look at how intelligent systems integrate with established SOPs and regulatory expectations. Rather than focusing on simple document generation—where AI has already made significant inroads—the real shift lies in reimagining the core of data integrity: edit checks and query management.

Industry experts are now exploring a transition from hard-coded, manual edit checks toward intelligent systems capable of real-time contextual judgment. The challenge isn't just whether AI can flag problematic data, but whether organizations can provide the retroactive benchmarking and validation evidence required to satisfy sponsors and regulators. Ultimately, the path forward involves a robust governance model, integrating AI validation plans and detailed visual audit trails that explain every automated decision with more transparency than traditional human processes.